Jonas Kuon

658 total citations
25 papers, 198 citations indexed

About

Jonas Kuon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jonas Kuon has authored 25 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Jonas Kuon's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Jonas Kuon is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Jonas Kuon collaborates with scholars based in Germany, Egypt and United States. Jonas Kuon's co-authors include Michael Thomas, Farastuk Bozorgmehr, Albrecht Stenzinger, Petros Christopoulos, Thomas Muley, Daniel Kazdal, Mark Kriegsmann, Rajiv Shah, Johannes Krisam and Helge Bischoff and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Thorax.

In The Last Decade

Jonas Kuon

24 papers receiving 193 citations

Peers

Countries citing papers authored by Jonas Kuon

Since Specialization

Citations

This map shows the geographic impact of Jonas Kuon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Kuon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Kuon more than expected).

Fields of papers citing papers by Jonas Kuon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Kuon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Kuon. The network helps show where Jonas Kuon may publish in the future.

Co-authorship network of co-authors of Jonas Kuon

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Kuon. A scholar is included among the top collaborators of Jonas Kuon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Kuon. Jonas Kuon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low Rates of Intrapulmonary Local Recurrence After Laser Metastasectomy: A Single-Center Retrospective Cohort Study of Colorectal Cancer Metastases 2025 ·Cancers ·Ahmad Shalabi, (unknown), Thomas Graeter, Stefan Welter, (unknown), Jonas Kuon	1
2	Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. 2024 ·Journal of Clinical Oncology ·Rajiv Shah, Martin Reck, Christian Grohé, Daniel C. Christoph, (unknown), Felix Carl Saalfeld, Nikolaj Frost, Hans‐Georg Kopp, Martin Faehling, Frank Griesinger, (unknown), Petra Hoffknecht, Jonas Kuon, (unknown), (unknown), (unknown), Michael Thomas	1
3	Real‐world data for precision cancer medicine—A European perspective 2023 ·Genes Chromosomes and Cancer ·Petros Christopoulos, Richard F. Schlenk, Daniel Kazdal, (unknown), Jochen K. Lennerz, Rajiv Shah, Jan Budczies, Nisar P. Malek, Stefan Fröhling, Richard Rosenquist, Peter Schirmacher, Farastuk Bozorgmehr, Jonas Kuon, Martin Reck, Michael Thomas, Albrecht Stenzinger	9
4	1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION 2023 ·Annals of Oncology ·(unknown), Simon Ekman, Florian Guisier, Cheryl Ho, Maria Di Blasi, (unknown), Jelena Cvetković, Daniel Kazdal, Jonas Kuon, (unknown), Albrecht Stenzinger, Stanley Wong, (unknown), Thomas W. McLean, Stewart A. Bergman, (unknown), (unknown), (unknown), Michael Thomas	3
5	1448P First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study 2023 ·Annals of Oncology ·Jonas Kuon, (unknown), Stefan Wilop, Dirk Behringer, Werner J. Blau, (unknown), Dimitri Flieger, Helmut Forstbauer, (unknown), (unknown), (unknown), Christian Schumann, (unknown), S Gütz	0
6	Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study 2023 ·Clinical Lung Cancer ·(unknown), Jonas Kuon, Rajiv Shah, Farastuk Bozorgmehr, Florian Eichhorn, (unknown), Albrecht Stenzinger, Claus Peter Heußel, Felix Herth, Michael Thomas, Petros Christopoulos	6
7	Unresectable undifferentiated sarcoma of the pulmonary artery 2022 ·Thorax ·Ahmad Shalabi, Thomas Graeter, Carlos Velandia, Jonas Kuon, (unknown)	1
8	Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis 2022 ·BMC Pulmonary Medicine ·(unknown), Martin Eichhorn, Petros Christopoulos, H. Winter, Claus Peter Heußel, Felix Herth, Rami A. El Shafie, Katharina Kriegsmann, Mark Kriegsmann, Albrecht Stenzinger, Helge Bischoff, Mike Thomas, Jonas Kuon	5
9	Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study 2021 ·Supportive Care in Cancer ·Jonas Kuon, (unknown), (unknown), J. Vogt, Anja Mehnert, Bernd Alt‐Epping, Birgitt van Oorschot, (unknown), Miriam Ahlborn, (unknown), (unknown), Christoph Kahl, A. Ruellan, (unknown), Thomas Kubin, (unknown), Andrea Heider, Florian Lordick, Michael Thomas, (unknown)	4
10	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report 2021 ·Case Reports in Oncology ·(unknown), Daniel Kazdal, Michael Thomas, Petros Christopoulos, Mark Kriegsmann, Regine Brandt, Anna‐Lena Volckmar, Martina Kirchner, Claus Peter Heußel, Albrecht Stenzinger, Jonas Kuon	6
11	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer 2021 ·Frontiers in Oncology ·(unknown), (unknown), Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, (unknown), Rajiv Shah, Anna‐Lena Volckmar, (unknown), L. Diekmann, (unknown), Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos	42
12	Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma 2021 ·Frontiers in Oncology ·(unknown), Farastuk Bozorgmehr, Daniel Kazdal, Jonas Kuon, Laura V. Klotz, Rajiv Shah, Florian Eichhorn, Mark Kriegsmann, Marc A. Schneider, Thomas Muley, Albrecht Stenzinger, Helge Bischoff, Petros Christopoulos	10
13	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives 2020 ·Translational Lung Cancer Research ·Sabine Wessels, Thomas Muley, Petros Christopoulos, Michael Meister, (unknown), Arne Warth, Esther Herpel, Simone Hummler, Ursula Klingmüller, Jonas Kuon, Claus Peter Heußel, Ralf Eberhardt, Felix Herth, H. Winter, Helge Bischoff, Albrecht Stenzinger, Martin Reck, Rudolf M. Huber, Michael Thomas, Marc A. Schneider	8
14	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial 2020 ·Trials ·Jonas Kuon, (unknown), Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, (unknown), Farastuk Bozorgmehr, (unknown), Meinhard Kieser, Marc A. Schneider, Michael Thomas	9
15	Nebenwirkungsmanagement in der Immunonkologie : Praktische Aspekte im Management immunvermittelter Nebenwirkungen unter immunonkologischer Therapie 2019 ·DMW - Deutsche Medizinische Wochenschrift ·Niels Reinmuth, Michael Bitzer, Barbara Deschler-Baier, Jürgen R. Fischer, Jonas Kuon, Jan Leipe, Justyna Rawluk, Christian Schulz, Claus Peter Heußel, Michael Schultheiß	1
16	Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment 2019 ·Oncology Research and Treatment ·Jonas Kuon, J. Vogt, Anja Mehnert, Bernd Alt‐Epping, Birgitt van Oorschot, (unknown), Miriam Ahlborn, (unknown), (unknown), Christoph Kahl, A. Ruellan, (unknown), Thomas Kubin, (unknown), Andrea Heider, Florian Lordick, Michael Thomas, (unknown)	19
17	Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial 2019 ·BMC Cancer ·Farastuk Bozorgmehr, (unknown), Johannes Krisam, Felix Lasitschka, Jonas Kuon, (unknown), Peter E. Huber, Laila König, Meinhard Kieser, Jürgen Debus, Michael Thomas, Stefan Rieken	28
18	Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial 2018 ·Annals of Oncology ·Jonas Kuon, Farastuk Bozorgmehr, Martin Schneider, Johannes Krisam, Felix Lasitschka, Monika Serke, Wolfgang Schuette, Nicolas Moosmann, Wolfgang Gleiber, Martin Faehling, Martin Wermke, (unknown), (unknown), Vincent van Laak, Ludwig Fischer von Weikersthal, (unknown), Christian Meyer zum Büschenfelde, J.R. Fischer, Mike Thomas	1
19	Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance 2018 ·Lung Cancer ·Petros Christopoulos, Marc A. Schneider, Farastuk Bozorgmehr, Jonas Kuon, Walburga Engel-Riedel, Jens Kollmeier, (unknown), Thomas Muley, Philipp A. Schnabel, Helge Bischoff, Christian Grohé, Monika Serke, Michael Thomas, Paul Fisch, Michael Meister	14
20	A longitudinal communication approach in advanced lung cancer: A qualitative study of patients’, relatives’ and staff's perspectives 2017 ·European Journal of Cancer Care ·Matthias Villalobos, (unknown), Katja Krug, Martina Kamradt, Michel Wensing, (unknown), Jonas Kuon, (unknown), (unknown), Eva C. Winkler, Joachim Szécsényi, Dominik Ose, Michael Thomas	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact